ArticleAnnals of the rheumatic diseases2020
Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis.
Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02257866 (Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Headache as the most common manifestation of giant cell arteritis?: a systematic review with meta-analysis.Rheumatology international · 2025Pooled it
- ACR Appropriateness Criteria® Noncerebral Vasculitis.Journal of the American College of Radiology : JACR · 2021Guideline
- Takayasu Arteritis and Giant Cell Arteritis: Results From a Cross-Sectional Study of 96 Italian Patients.Immunity, inflammation and disease · 2026Article
- Large vessel vasculitis reframed: integrating conceptual shifts and evidence into practice for Takayasu arteritis and giant cell arteritis.Journal of rheumatic diseases · 2026Review
- Challenges and Future Trends in Large Vessel Vasculitis.Circulation · 2026Review
- Use ofACR open rheumatology · 2025Article
- Performance of the modified 2022 ACR/EULAR giant cell arteritis classification criteria without age restriction for discriminating from Takayasu arteritis.Arthritis research & therapy · 2025Article
- Mitochondrial-mediated inflammation and platelet activation in giant cell arteritis.Clinical immunology (Orlando, Fla.) · 2023Article
- Associations of microcirculation damage on nailfold capillaroscopy with supra-aortic severe ischemic events in patients with Takayasu arteritis.Clinical rheumatology · 2023Article
- Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis.Clinical immunology (Orlando, Fla.) · 2023Article
- Takayasu's arteritis in an adolescent with fever of unknown origin: the contribution of PET-CT in the diagnosis.BMJ case reports · 2022Article
- Large-vessel vasculitis.Nature reviews. Disease primers · 2022Review
- Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.Journal of neuroinflammation · 2021Review
- Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis.Rheumatology (Oxford, England) · 2021Article
- Analysis of Development Mechanism of Giant Cell Arteritis in Nude Mouse Model through Color Duplex Sonography and Computerized Tomography Nanocontrast Agent.BioMed research international · 2021Article
- Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients.European journal of nuclear medicine and molecular imaging · 2020Article
- Autoimmunity in 2019.Clinical reviews in allergy & immunology · 2020Review
- [Long-term complications, monitoring and interventional treatment of large vessel vasculitis].Zeitschrift fur Rheumatologie · 2020Review
- [Treatment of Takayasu arteritis].Zeitschrift fur Rheumatologie · 2020Review
- Giant Cell Arteritis versus Takayasu Arteritis: An Update.Mediterranean journal of rheumatology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo compare the presence of head, neck and upper extremity symptoms in patients with Takayasu's (TAK) and giant cell arteritis (GCA) and their association with vascular inflammation assessed by
methodsPatients with TAK and GCA underwent clinical and imaging assessments within 24 hours, blinded to each other. Vascular inflammation was defined as arterial FDG-PET uptake greater than liver by visual assessment. Arterial damage was defined as stenosis, occlusion, or aneurysm by MRA. Clinically reported symptoms were compared with corresponding imaging findings using generalised mixed model regression. Cranial symptoms were studied in association with burden of arterial disease in the neck using ordinal regression.
resultsParticipants with TAK (n=56) and GCA (n=54) contributed data from 270 visits. Carotidynia was reported only in patients with TAK (21%) and was associated with vascular inflammation (p<0.01) but not damage (p=0.33) in the corresponding carotid artery. Posterior headache was reported in TAK (16%) and GCA (20%) but was only associated with corresponding vertebral artery inflammation and damage in GCA (p<0.01). Arm claudication was associated with subclavian artery damage (p<0.01) and inflammation (p=0.04) in TAK and with damage in GCA (p<0.01). Patients with an increased burden of damaged neck arteries were more likely to experience positional lightheadedness (p<0.01) or a major central nervous system event (p=0.01).
conclusionThe distribution of symptoms and association with imaging abnormalities differs in patients with TAK and GCA. These findings may help clinicians predict associated FDG-PET and MRA findings based on a specific clinical symptom. CLINICAL TRIAL REGISTRATION NUMBER: NCT02257866.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.